<DOC>
	<DOCNO>NCT00000977</DOCNO>
	<brief_summary>To determine minimal effective ( immunogenic ) dose vaccine asymptomatic HIV-1 seropositive individual &gt; 400 cells/mm3 ( CD4 ) . To determine dose-response 4 fold escalation immunize dose . To describe cellular humoral immune response HIV-1 immunized individual . To describe effect immunization general immunological , virological clinical parameter . To evaluate safety inject recombinant gp160 population . To evaluate extent variability different lot gp160 ( arm C1 C2 ) . It might possible increase immune response induce new type immune response HIV infect individual mean vaccine , could result immunological , virological clinical benefit .</brief_summary>
	<brief_title>Active Immunization Asymptomatic , HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen : A Phase I/II Study Immunogenicity Toxicity</brief_title>
	<detailed_description>It might possible increase immune response induce new type immune response HIV infect individual mean vaccine , could result immunological , virological clinical benefit . ORIGINAL DESIGN : Patients randomize one five group receive , intramuscularly , one four dosage gp160 hepatitis B vaccine control . Treatments give 0 , 1 , 3 , 6 , 9 , 12 month patient follow 2 year . Patients 5 group option switch another dosage group interim analysis 6 month show significant difference patient response . AMENDED : 10/23/90 52 eligible patient randomize one 6 study group . Five group 8 individual receive one 4 dosage level gp160 ( Groups A , B , C1 , C2 , D ) , 12 patient receive single dosage level hepatitis B vaccine control ( Group E ) . Per 2/19/92 amendment , patient may elect continue receive vaccine beyond 12 month , dose give either every 3 month every 6 month .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Acute use ( &lt; 14 day ) acyclovir Herpes simplex virus infection ketoconazole symptomatic Candida infection . An additional group 20 patient may add study . Patients ACTG 148 repeatedly negative delayedtype hypersensitivity ( DTH ) reaction reach third dose ID gp160 32 mcg fail develop new proliferative response option , 2month interval , enter protocol . They must meet inclusion exclusion criterion apply protocol . Patients CD4 count 400 500 cells/mm3 must inform recommended zidovudine ( AZT ) therapy sign inform consent statement decline AZT therapy . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Fever &gt; 100 degree F persist &gt; 15 day 30day interval without definable cause . Recurrent oral candidiasis . Multidermatomal herpes zoster . Biopsyproven hairy leukoplakia . Fatigue/malaise &gt; 1 month duration interfere normal activity . Evidence clinically significant central nervous system dysfunction assess neurological exam . Involuntary weight loss &gt; 10 lb 10 percent normal weight 6 month interval . Diarrhea ( &gt; 3 stools/day ) 30 day without definable cause . Concurrent Medication : Excluded : Antiretroviral agent proven potential efficacy potential immunoenhancing immunosuppressive drug . Patients follow excluded : Known hypersensitivity insect cell baculovirus . Abnormal chest xray take within 3 month study entry . Systemic symptom think due HIV infection ( lymphadenopathy ) . Evidence clinically significant central nervous system dysfunction assess neurological exam . Unwilling unable give write informed consent . Prior Medication : Excluded within 90 day study entry : Zidovudine ( AZT ) , didanosine ( ddI ) , potential antiretroviral immunomodulating agent . Active substance abuse ( either continue daily alcohol abuse intravenous drug use ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>HIV Seropositivity</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Therapeutic Vaccine</keyword>
</DOC>